These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 38931847)
1. Amino Acid Biosynthesis Inhibitors in Tuberculosis Drug Discovery. Guida M; Tammaro C; Quaranta M; Salvucci B; Biava M; Poce G; Consalvi S Pharmaceutics; 2024 May; 16(6):. PubMed ID: 38931847 [TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
3. [Recent progress in mycobacteriology]. Okada M; Kobayashi K Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602 [TBL] [Abstract][Full Text] [Related]
4. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery. de Wet TJ; Warner DF; Mizrahi V Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123 [TBL] [Abstract][Full Text] [Related]
5. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Tomioka H Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755 [TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach. Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549 [TBL] [Abstract][Full Text] [Related]
7. Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance. Perveen S; Kumari D; Singh K; Sharma R Eur J Med Chem; 2022 Feb; 229():114066. PubMed ID: 34973508 [TBL] [Abstract][Full Text] [Related]
8. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal. Cohen KA; Abeel T; Manson McGuire A; Desjardins CA; Munsamy V; Shea TP; Walker BJ; Bantubani N; Almeida DV; Alvarado L; Chapman SB; Mvelase NR; Duffy EY; Fitzgerald MG; Govender P; Gujja S; Hamilton S; Howarth C; Larimer JD; Maharaj K; Pearson MD; Priest ME; Zeng Q; Padayatchi N; Grosset J; Young SK; Wortman J; Mlisana KP; O'Donnell MR; Birren BW; Bishai WR; Pym AS; Earl AM PLoS Med; 2015 Sep; 12(9):e1001880. PubMed ID: 26418737 [TBL] [Abstract][Full Text] [Related]
9. Fighting the tuberculosis epidemic in the Western Pacific region: current situation and challenges ahead. van Maaren PJ Kekkaku; 2010 Jan; 85(1):9-16. PubMed ID: 20143671 [TBL] [Abstract][Full Text] [Related]
10. BacPROTACs targeting Clp protease: a promising strategy for anti-mycobacterial drug discovery. Bonjorno AF; Pavan AR; Fernandes GFS; Scarim CB; Castagnolo D; Dos Santos JL Front Chem; 2024; 12():1358539. PubMed ID: 38357296 [TBL] [Abstract][Full Text] [Related]
12. Drug discovery in tuberculosis. New drug targets and antimycobacterial agents. Campaniço A; Moreira R; Lopes F Eur J Med Chem; 2018 Apr; 150():525-545. PubMed ID: 29549838 [TBL] [Abstract][Full Text] [Related]
13. Overview of drug-resistant tuberculosis worldwide. Velayati AA; Farnia P; Farahbod AM Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S161. PubMed ID: 28043527 [TBL] [Abstract][Full Text] [Related]
14. Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)--a novel, patentable approach to limit the emergence of XDR-TB. Martins M Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):110-7. PubMed ID: 21517742 [TBL] [Abstract][Full Text] [Related]
15. Drug development against tuberculosis: Past, present and future. Vasava MS; Bhoi MN; Rathwa SK; Borad MA; Nair SG; Patel HD Indian J Tuberc; 2017 Oct; 64(4):252-275. PubMed ID: 28941848 [TBL] [Abstract][Full Text] [Related]
16. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. Centers for Disease Control and Prevention (CDC) MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162 [TBL] [Abstract][Full Text] [Related]
17. Treatment efficacy of drug-resistant tuberculosis in Bashkortostan, Russia: A retrospective cohort study. Yunusbaeva M; Borodina L; Alekseev P; Davydov R; Yunusbaev U; Sharipov R; Bilalov F; Yunusbayev B Int J Infect Dis; 2019 Apr; 81():203-209. PubMed ID: 30794942 [TBL] [Abstract][Full Text] [Related]
18. Genomic, phenotypic and demographic characterization of Losev Y; Rubinstein M; Nissan I; Haviv P; Barsky Y; Volinsky M; Bar-Giora G; Zouher T; Hamawi M; Valenci GZ; Kutikov I; Shwartz HK; Dveyrin Z; Chemtob D; Rorman E Front Cell Infect Microbiol; 2023; 13():1196904. PubMed ID: 37928179 [TBL] [Abstract][Full Text] [Related]
19. The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia. Shibabaw A; Gelaw B; Gebreyes W; Robinson R; Wang SH; Tessema B PLoS One; 2020; 15(2):e0229040. PubMed ID: 32053661 [TBL] [Abstract][Full Text] [Related]